ID   NCI-H2869
AC   CVCL_V001
SY   H2869; H-2869; NCIH2869
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_V001
DR   Cell_Model_Passport; SIDM00519
DR   Cosmic; 1995418
DR   Cosmic-CLP; 1240138
DR   DepMap; ACH-002135
DR   EGA; EGAS00001000978
DR   GDSC; 1240138
DR   GEO; GSM1669830
DR   PharmacoDB; H2869_432_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54908010
RX   PubMed=23830731;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.6%; South Asian=0.96%; European, North=63.53%; European, South=34.91% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,11
ST   D16S539: 13
ST   D5S818: 12,13
ST   D7S820: 7,8
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 22
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//